TP53 and breast cancer: Although variant calling from RNA‐seq data is limited to expressed regions of the genome, mutations in important BC genes such as PIK3CA, TP53, and ERBB2, as well as pathways can be reliably detected, which may be used to inform clinical trials and eventual reporting to the clinic.